# A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

> **NCT02314442** · PHASE1 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 70 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** ALN-PCSSC
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT02314442
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02314442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02314442, "A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02314442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*